PulseExploreJournal ClubTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 22, 2026Cancer Research

Abstract A018: INPP4B Downregulation and AKT1 Dependence as Emerging Therapeutic Vulnerabilities in TMPRSS2:ERG Fusion Prostate Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

BEBetul Ersoy-FazliogluFXFang XieLCLuigi Cecchi

Discussion

Loading...

Member takes

Overview

Integrative analyses reveal INPP4B downregulation and AKT1 dependence in TMPRSS2:ERG fusion prostate cancer, suggesting new therapeutic vulnerabilities.

Key Points

  • This research explores how INPP4B downregulation affects AKT1 dependence in TMPRSS2:ERG fusion prostate cancer.
  • Integrated analysis of prostate cancer datasets
  • Use of genetically engineered mouse models
  • CRISPRi for gene perturbation
  • Evaluation of ATA-001 and capivasertib in functional assays
  • INPP4B downregulation is prevalent in TMPRSS2:ERG fusion tumors
  • AKT pathway activation occurs regardless of PTEN status
  • ATA-001 shows comparable efficacy to capivasertib in inhibiting tumor growth
  • ERG expression suppresses PI3K signaling, creating dependencies on AKT1

Cite This Study

Ersoy-Fazlioglu et al. (2026) studied this question.

synapsesocial.com/papers/6971bfdff17b5dc6da021f56https://doi.org/10.1158/1538-7445.prostateca26-a018
View Full Paper
Ask AI
Bookmark
Share